AAO 2024: EyePoint’s EYP-1901 proves non-inferiority to aflibercept in DAVIO 2
While adverse events (AEs) were reported for 97% of trial participants, such cases were predominantly mild to moderate.
View ArticleAAO 2024: Nanoscope Therapeutics’ MCO-010 RESTOREs vision in RP patients
This trial investigated the potential of Nanoscope Therapeutics' MCO-010 to restore vision in patients with retinitis pigmentosa (RP).
View ArticleWorld Osteoporosis Day calls for urgent action to prevent fragility fractures
The IOF highlights the importance of collaborative efforts in treating osteoporosis, ensuring appropriate care globally.
View ArticleAAO 2024: NMA reveals Vabysmo’s superior CST improvement over Eylea HD
This NMA serves to bridge the gap between trials for both therapies and compare them to one another based on existing data.
View ArticleEU Critical Medicines Act: closer to ending overreliance on Asian manufacturers
China's virtual monopoly on the supply of many APIs could be dangerous for the security of medicine supply to Western countries.
View ArticleRedlining’s lasting impact on asthma disparities
The enduring effects of redlining on public health, particularly on asthma prevalence, provide a striking example of how discriminatory housing policies from the 20th century continue to shape the...
View ArticleSouth Korean pricing reform suggests more flexible drug reimbursement...
South Korea’s Ministry of Health and Welfare recently disclosed its proposal to revise the drug reimbursement and price-setting regulations.
View ArticleIDWeek 2024: Kalihinol analogue shows promise as targeted antimalarial therapy
The Kalihinol analogue is an innovative approach to malaria treatment, targeting the apicoplast to undermine P falciparum’s functions.
View ArticleRoche to leverage Dyno Therapeutics tech for novel gene therapies in neuro...
With the formation of a new strategic partnership, Dyno Therapeutics is responsible for the development of novel AAV capsids.
View Article